Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...
Baby Center (worldwide) on MSN1d
Here's the vaccine schedule to follow for your baby or older childVaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback